Durable Hematologic Response in Therapy-Related Myelodysplastic Syndrome During Nivolumab Treatment for Metastatic Melanoma: A Case Report. [PDF]
Hamza FNM +3 more
europepmc +1 more source
Neoadjuvant Therapy for Non‐Small Cell Lung Cancer: Recent Advances and Future Directions
ABSTRACT Neoadjuvant therapy has become an integral component of the multidisciplinary management of resectable non–small cell lung cancer (NSCLC). The introduction of immune checkpoint inhibitors (ICIs) has transformed the perioperative treatment landscape by improving pathological response rates, reducing the risk of recurrence, and offering the ...
Hao An +15 more
wiley +1 more source
Biomarkers of nivolumab benefit in resectable non-small cell lung cancer. [PDF]
Cascone T +30 more
europepmc +1 more source
Contemporary Multimodal Management of Cutaneous Malignancies: Surgery, Radiotherapy, Systemic Therapy, Molecular Targeting and Immunotherapy. [PDF]
Kowalczyk D +5 more
europepmc +1 more source
Intratumoral CTLA‐4 Blockade: Decoupling Local Immune Remodeling From Systemic Toxicity
MedComm – Oncology, Volume 5, Issue 4, December 2026.
Luyan Chen +4 more
wiley +1 more source
Real-world safety and effectiveness of nivolumab in patients with cancer of unknown primary: results from a nationwide post-marketing surveillance in Japan. [PDF]
Kawasaki A +4 more
europepmc +1 more source
Cabozantinib Monotherapy for Metastatic Renal Cell Carcinoma Involving Hemodialysis: Two Case Reports. [PDF]
Nara T +6 more
europepmc +1 more source
Variation in guideline decision-making: a cross-sectional study of oncology compendium panels. [PDF]
Strohbehn GW +4 more
europepmc +1 more source

